Company Overview of Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for patients in the United States. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, and skin diseases and conditions. The company also provides patient assistance programs. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1997. The company was incorporated in 1968 and is based in Ea...
One Health Plaza
East Hanover, NJ 07936-1080
Founded in 1968
Key Executives for Novartis Pharmaceuticals Corporation
President, US Country Head and President of Novartis Corporation
Chief Financial & Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2015.
Novartis Pharmaceuticals Corporation Key Developments
FDA Approves Novartis Drug Odomzo (Sonidegib) for Locally Advanced Basal Cell Carcinoma (laBCC), a Form of Skin Cancer
Jul 24 15
Novartis Pharmaceuticals Corporation announced the US Food and Drug Administration (FDA) has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The Odomzo approval was based on the demonstration of a durable objective response rate (ORR) in an international, multi-center, double-blind, randomized, two-arm, non-comparative trial in patients with laBCC not amenable to local therapy or metastatic basal cell carcinoma (mBCC). Patients with laBCC treated with Odomzo 200 mg (n=66) were followed for at least 12 months unless discontinued earlier. The ORR was 58% (95% confidence interval: 45, 70), consisting of 5% (n=3) complete responses (CR) and 53% (n=35) partial responses (PR). A pre-specified sensitivity analysis using an alternative definition for CR, defined as at least a PR according to MRI and/or photography and no evidence of tumor on biopsy of residual lesion, yielded a CR rate of 20%. Among the 38 patients with an objective response, 31 patients (82%) have ongoing responses ranging from at least 1.9 to 18.6 months and the median duration of response has not been reached. The most serious risks of Odomzo are embryofetal toxicity and musculoskeletal adverse reactions including rhabdomyolysis. Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase (CK) elevations, may occur with Odomzo and other drugs which inhibit the hedgehog pathway. The incidence of musculoskeletal adverse reactions in patients with laBCC treated with Odomzo 200 mg was 68%, with 9% reported as grade 3 or 4. Adverse reactions occurring in more than 10% of patients treated with Odomzo 200 mg were muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, and pruritus. The most frequent grade 3 and 4 laboratory abnormalities occurring in at least 5% of patients were serum creatine kinase (CK) elevation and lipase elevation.
Novartis Pharmaceuticals Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 11:40 AM
May 17 15
Novartis Pharmaceuticals Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 11:40 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Stephen Rubino, Global Head, BD and New Products Marketing, Cell & Gene Therapy Unit.
Novartis Pharmaceuticals Corporation Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 08:30 AM
May 4 15
Novartis Pharmaceuticals Corporation Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 08:30 AM. Venue: Time Warner Center, New York, United States. Speakers: Peter Waibel, Head US Patent Litigation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|